CLINICAL-DIAGNOSTIC FEATURES AND MODERN TREATMENT PRINCIPLES OF MENSTRUAL CYCLE DISORDERS IN WOMEN OF REPRODUCTIVE AGE
Keywords:
menstrual cycle disorders, reproductive endocrinology, hypothalamic-pituitary-ovarian axis, Polycystic Ovary Syndrome (PCOS), insulin resistance, targeted therapy, ovulatory dysfunction, hyperandrogenism.Abstract
Menstrual cycle disorders among women of reproductive age represent a multifaceted gynecological, endocrine, and metabolic challenge. These irregularities—ranging from oligomenorrhea and amenorrhea to abnormal uterine bleeding—are primary contributors to female infertility, metabolic syndrome, and significant reductions in overall quality of life. Despite the high prevalence of these conditions, traditional therapeutic paradigms have often relied heavily on symptom management rather than addressing the root pathophysiological causes.
References
1.ACOG Committee on Practice Bulletins—Gynecology. (2022). Management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstetrics & Gynecology, 122(1), 176–185.
2.Speroff, L., & Fritz, M. A. (2020). Clinical Gynecologic Endocrinology and Infertility (9th ed.). Lippincott Williams & Wilkins.
3.Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., ... & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1), 1-18.
4.Fraser, I. S., Critchley, H. O., Broder, M., & Munro, M. G. (2018). The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Seminars in Reproductive Medicine, 29(5), 383-390.
5.Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., ... & Yildiz, B. O. (2023). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602-1618.
6.Chrousos, G. P., & Kino, T. (2020). Glucocorticoid signaling in the cell: Expanding clinical implications to complex human physiologic and pathologic conditions. Annals of the New York Academy of Sciences, 1179, 153–166.
7.Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2021). Polycystic ovary syndrome. The Lancet, 370(9588), 685-697.
8.Diamanti-Kandarakis, E., & Dunaif, A. (2019). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33(6), 981-1030.
9.Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., ... & Simoncini, T. (2019). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 28(12), 969-973.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal